Otomobiltamir
Biology & Genetics

Research Integrity News: Gene-Editing Trial, Questioned Disease Data and Rising Retractions

Published Nov 14, 2026 Reads 523 By Retraction Watch Staff

A child’s death in a gene-editing trial, scrutiny of infectious disease data and rising retractions headline a week of research integrity stories.

Research Integrity News: Gene-Editing Trial, Questioned Disease Data and Rising Retractions

A child’s death during a gene-editing trial in China, questions about genetic data from an infectious disease research group, and a rise in retractions of older papers put research accountability in focus this week. Together, these cases point to a persistent challenge: scrutiny often arrives long after research has shaped scientific records and public debate.

Questions of oversight and data quality

Chinese authorities fired researchers after a child died during a gene-editing trial, a case that had previously gone unreported publicly. The episode puts attention on how clinical research involving gene editing is monitored and what information reaches the public when serious outcomes occur.

Separately, critics questioned genetic data associated with a prolific infectious disease research group, describing the data as baffling. The questions connect to a broader effort to track pathogens around the world, where the reliability of underlying data matters to the conclusions researchers draw from it.

Retractions of older papers are also increasing, raising a difficult question for journals and institutions: when should flawed work be removed from the literature? The passage of time can make investigations harder, while leaving unreliable findings in circulation can affect later research.

Research integrity systems under pressure

Other developments point to strains in the systems meant to catch problems. A preprint study reported that AI outperformed scientists at identifying errors in clinical research papers. That finding adds to debates over how automated screening might contribute to publication checks, even as concerns grow about AI-generated papers appearing under prominent academics’ names and the limits of enforcing journal AI policies.

Elsevier acquired Clear Skies to strengthen research integrity screening. Elsewhere, a study tested whether comments on PubPeer make a difference, and a researcher examined what the separation between publishers and journals means for scientific governance. These efforts address different parts of the same problem: who spots questionable work, who acts on it, and how independent those decisions are.

In South Korea, data show that research misconduct cases can remain unresolved for years. Meanwhile, a Springer Nature journal retracted a paper concerning trans youth after researchers used minors’ data without consent. The cases underscore how delays and research practices can leave participants, institutions and the published record exposed to unresolved questions.

Publication incentives and credit

Debate over publication volume is continuing on several fronts. The American Journal of Political Science has capped submissions at three per author each year, while submissions to a preprint server are still rising despite an author cap. A separate analysis asks what it costs to produce a research paper; other commentary questions whether a glut of disciplinary reviews is growing faster than the evidence those reviews can assess.

Questions of credit remain just as pressing. Researchers argue that women aren’t receiving full recognition for their contributions, and a separate discussion says acknowledgments alone may not adequately recognize the invisible labor that keeps science running. A proposal for peer review in the age of AI suggests reviewers focus less on writing, while a preprint platform’s offer to pay researchers for reviews has prompted questions of its own.

Preprinting has also revived a core debate: whether sharing work before formal review diminishes the value of peer review. The answer will shape how researchers and journals divide responsibility for assessing claims as manuscripts circulate faster.

Retractions and misconduct in the wider record

Plagiarism allegations and an author’s retraction request have been under investigation at Elsevier for a year. A cancer researcher has lost another paper over image issues, and a journal editor said he was more interested in addressing problems in a current submission than investigating a paper from 23 years earlier. Each case highlights the practical question of how journals should weigh new concerns against limited editorial time.

Other stories included a data analysis arguing that five fraudulent papers attributed to researcher Francesca Gino may indicate further problems, and a report that a Galway University expert on fake news claimed a false doctorate. South Korean cloning researcher Woo-Suk Hwang also lost his South Korean nationality and acquired UAE citizenship.

Retraction Watch’s database contains more than 68,000 retractions, while its list of COVID-19 retractions is nearing 800. Its Hijacked Journal Checker has passed 450 entries, and its list of mass editorial resignations exceeds 50.

What to watch next

Other discussions range from the scientific fraud alleged behind the IEEE’s prestige to the claim that university rankings could suffer if AI undermines journal publishing. A proposed 2026 Council of Science Editors symposium session, scheduled for November 19, will examine incentives to publish and accountability across stakeholders.

The common thread is pressure on the institutions that decide what counts as credible research. As AI expands screening capacity and publication volumes keep climbing, journals and research organizations will need to show not just that concerns are detected, but that they are resolved in a timely and transparent way.

Source: Retraction Watch Staff · retractionwatch.com

Discussion

Sign in to join the discussion.